Incidental Gallbladder Cancer Detected During Laparoscopic Cholecystectomy: Conversion to Extensive Resection is a Feasible Choice

Overview

Journal Front Surg

Specialty General Surgery

Date 2024 Sep 20

PMID 39301169

Authors

Di Zeng

Yaoqun Wang

Ningyuan Wen

Jiong Lu

Bei Li

Nansheng Cheng

Affiliations

Soon will be listed here.

Abstract

Background: Re-resection is recommended for patients with incidental gallbladder carcinoma (iGBC) at T1b stage and above. It is unclear whether continuation of laparoscopic re-resection (CLR) for patients with intraoperatively detected iGBC (IDiGBC) is more beneficial to short- and long-term clinical outcomes than with conversion to radical extensive-resection (RER).

Methods: This single-centre, retrospective cohort study of patients with iGBC was conducted between June 2006 and August 2021. Patients who underwent immediate reresection for T1b or higher ID-iGBC were enrolled. Propensity score matching (PSM) was used to match the two groups (CLR and RER) of patients, and differences in clinical outcomes before and after matching were analyzed.

Result: A total of 102 patients with ID-iGBC were included in this study. 58 patients underwent CLR, and 44 underwent RER. After 1:1 propensity score matching, 56 patients were matched to all baselines. Patients in the RER group had a lower total postoperative complication rate, lower pulmonary infection rate, and shorter operation time than those in the CLR group did. Kaplan-Meier analysis showed that the overall survival rate of patients who underwent CLR was significantly lower than that of patients who underwent RER. Multivariate analysis showed that CLR, advanced T stage, lymph node positivity, and the occurrence of postoperative ascites were adverse prognostic factors for the overall survival of patients.

Conclusion: Patients with ID-iGBC who underwent RER had fewer perioperative complications and a better prognosis than those who underwent CLR. For patients with ID-iGBC, conversion to radical extensive-resection appears to be a better choice.

References

Goetze T, Paolucci V . Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma: analysis of the German registry. Ann Surg. 2007; 247(1):104-8. DOI: 10.1097/SLA.0b013e318154bf5d. View

Pyo J, Son B, Lee H, Oh I, Chung K . Incidental Carcinoma after Cholecystectomy for Benign Disease of the Gallbladder: A Meta-Analysis. J Clin Med. 2020; 9(5). PMC: 7290945. DOI: 10.3390/jcm9051484. View

Isambert M, Leux C, Metairie S, Paineau J . Incidentally-discovered gallbladder cancer: When, why and which reoperation?. J Visc Surg. 2011; 148(2):e77-84. DOI: 10.1016/j.jviscsurg.2011.02.005. View

Aloia T, Jarufe N, Javle M, Maithel S, Roa J, Adsay V . Gallbladder cancer: expert consensus statement. HPB (Oxford). 2015; 17(8):681-90. PMC: 4527853. DOI: 10.1111/hpb.12444. View

Yuza K, Sakata J, Prasoon P, Hirose Y, Ohashi T, Toge K . Long-term outcomes of surgical resection for T1b gallbladder cancer: an institutional evaluation. BMC Cancer. 2020; 20(1):20. PMC: 6945689. DOI: 10.1186/s12885-019-6507-2. View

Regmi P, Hu H, Chang-Hao Y, Liu F, Ma W, Ran C . Laparoscopic surgery for oncologic extended resection of T1b and T2 incidental gallbladder carcinoma at a high-volume center: a single-center experience in China. Surg Endosc. 2020; 35(12):6505-6512. DOI: 10.1007/s00464-020-08146-7. View

Benson A, DAngelica M, Abbott D, Anaya D, Anders R, Are C . Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(5):541-565. DOI: 10.6004/jnccn.2021.0022. View

Oh D, Lee K, Lee D, Yoon J, Kim T, Bang J . Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022; 7(6):522-532. DOI: 10.1016/S2468-1253(22)00043-7. View

Lujan J, Almeida A, Lopez-Olaondo L, Rotellar F . Laparoscopic radical hepatectomy and lymphadenectomy for incidental gallbladder cancer. Surgical technique with ICG fluorescence enhancement. Surg Oncol. 2022; 42:101756. DOI: 10.1016/j.suronc.2022.101756. View

10.

Schafer M, Krahenb hl L, Buchler M . Comparison of adhesion formation in open and laparoscopic surgery. Dig Surg. 1998; 15(2):148-52. DOI: 10.1159/000018609. View

11.

Xiao Z, Shi Z, Hu L, Gao Y, Zhao J, Liu Y . A new nomogram from the SEER database for predicting the prognosis of gallbladder cancer patients after surgery. Ann Transl Med. 2020; 7(23):738. PMC: 6989982. DOI: 10.21037/atm.2019.11.112. View

12.

Baiu I, Visser B . Gallbladder Cancer. JAMA. 2018; 320(12):1294. DOI: 10.1001/jama.2018.11815. View

13.

Goetze T, Paolucci V . The prognostic impact of positive lymph nodes in stages T1 to T3 incidental gallbladder carcinoma: results of the German Registry. Surg Endosc. 2011; 26(5):1382-9. DOI: 10.1007/s00464-011-2044-z. View

14.

Kondo S, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M . Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg. 2008; 15(1):41-54. PMC: 2794356. DOI: 10.1007/s00534-007-1279-5. View

15.

Lundgren L, Muszynska C, Ros A, Persson G, Gimm O, Andersson B . Management of incidental gallbladder cancer in a national cohort. Br J Surg. 2019; 106(9):1216-1227. DOI: 10.1002/bjs.11205. View

16.

Kasumova G, Tabatabaie O, Najarian R, Callery M, Ng S, Bullock A . Surgical Management of Gallbladder Cancer: Simple Versus Extended Cholecystectomy and the Role of Adjuvant Therapy. Ann Surg. 2017; 266(4):625-631. DOI: 10.1097/SLA.0000000000002385. View

17.

Pitt S, Jin L, Hall B, Strasberg S, Pitt H . Incidental gallbladder cancer at cholecystectomy: when should the surgeon be suspicious?. Ann Surg. 2014; 260(1):128-33. DOI: 10.1097/SLA.0000000000000485. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Kim S, Kang J, Lee J, Lee H, Oh S, Jang J . Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol. 2019; 30(5):788-795. DOI: 10.1093/annonc/mdz058. View

20.

Hundal R, Shaffer E . Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014; 6:99-109. PMC: 3952897. DOI: 10.2147/CLEP.S37357. View